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Processes Institute, Northwestern University, Evanston, IllinoisABSTRACT We use molecular dynamics simulations to characterize the influence of cholesterol (Chol) on the interaction
between the anticancer drug doxorubicin (DOX) and a dipalmitoyl phosphatidylcholine/Chol lipid bilayer. We calculate the poten-
tial of mean force, which gives us an estimate of the free energy barrier for DOX translocation across the membrane.We find free
energy barriers of 23.1 5 3.1 kBT, 36.8 5 5.1 kBT, and 54.5 5 4.7 kBT for systems composed of 0%, 15%, and 30% Chol,
respectively. Our predictions agree with Arrhenius activation energies from experiments using phospholipid membranes,
including 20 kBT for 0% Chol and 37.2 kBT for 20% Chol. The location of the free energy barrier for translocation across the
bilayer is dependent on composition. As Chol concentration increases, this barrier changes from the release of DOX into the
water to flip-flop over the membrane center. The drug greatly affects local membrane structure by attracting dipalmitoyl phos-
phatidylcholine headgroups, curving the membrane, and allowing water penetration. Despite its hydrophobicity, DOX facilitates
water transport via its polar groups.INTRODUCTIONGrowing interest in liposomal drug delivery presents the
problem of finding optimal liposome compositions (1–4).
Finding the correct balance between efficacy and
toxicity—one of the major obstacles in drug delivery—is
dependent on accurate drug release profiles. A systematic
knowledge of the effect of composition on release rate
will provide greater control and help develop carriers opti-
mized for particular drugs. Optimization of these liposomes
requires a thorough understanding of basic molecular
interactions within the liposomal membrane. Moreover,
understanding the mechanism of drug translocation through
lipid layers may shed light on transport processes across
biological membranes. To pursue this goal, we study here
the role of cholesterol on drug-bilayer interaction, including
drug translocation and structural effects on the membrane.
The dependence of transport on liposome composition has
been studied experimentally for decades (5,6), however
there remains a wealth of knowledge to uncover. Both theo-
retical and experimental efforts will be required to achieve
a comprehensive understanding of drug-bilayer interaction.
This work can help in the broader understanding of molec-
ular transport in biological membranes, unmediated by
proteins.
Doxorubicin (DOX) is an anticancer drug that has been
studied for several decades (7,8) and is used clinically to
treat a variety of cancers, including various types of carci-
noma and sarcoma. Fig. 1 displays the structure of DOX,
which consists of a hydrophobic anthracycline backbone,
along with several active sites, including an amine group,Submitted January 28, 2011, and accepted for publication June 8, 2011.
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0006-3495/11/07/0378/8 $2.00ketone groups, and hydroxyl groups (9). It is thus largely
hydrophobic with the ability for electrostatic interaction.
The accepted mechanism of action for DOX is intercalation
in the double helix of DNA, which prevents transcription.
Because this mechanism is not specific to tumor cells,
side effects such as the hand-foot syndrome have prevented
more widespread use of the drug. To increase circu-
lation time and decrease side effects through specificity,
DOX has been formulated in liposomal drug carriers
(2,10,11). The membrane of one these formulations,
DOXIL, is composed of hydrogenated soy phosphatidyl-
choline (HSPC) and cholesterol (Chol).
The membrane modeled in this study is a binary mixture
of dipalmitoyl phosphatidylcholine (DPPC) and Chol,
which we consider to represent the membrane of a liposomal
drug carrier. DPPC contains two 16-carbon (palmitoyl)
chains, as compared to 16-carbon and 18-carbon found in
HSPC. DPPC is chosen for modeling because it is a common
phospholipid, well studied both by simulation and experi-
ment. The zwitterionic DPPC molecule contains a positively
charged choline group and a negatively charged phosphate
group. These headgroups are connected to the two saturated
palmitoyl 16-carbon chains via a glycerol backbone.
Cholesterol is short and rigid, essentially filling in the
gaps between DPPC molecules. It has the power to decrease
the membrane area per lipid, condense the membrane, and
bring order to DPPC acyl chains at various temperatures
(12,13). Additionally, the smooth a-face of cholesterol
encourages the saturated chains of DPPC to straighten,
further ordering and rigidifying the bilayer (14). Cholesterol
is therefore included in liposomal drug carrier formulations
to provide the rigidity necessary to prevent rapid drug
leakage.doi: 10.1016/j.bpj.2011.06.015
FIGURE 1 Chemical representation of neutral doxorubicin.
Cholesterol Role in Drug Translocation 379In this study, we characterize membrane structure and
permeability at different Chol concentrations in the pres-
ence of DOX. Permeability is characterized by the free
energy barrier necessary for the translocation of DOX across
the membrane. This is found from the potential of mean
force (PMF) of the drug calculated at many different posi-
tions throughout the membrane. The PMF tells us the
amount of work needed for DOX to penetrate from the
bulk water to a given depth in the membrane. We perform
molecular dynamics (MD) simulations to calculate the
potential of mean force, and to study changes in membrane
structure as a function of both Chol concentration and DOX
location. Simulations provide atomistic detail of bilayer
structure, readily allowing the calculation of order parame-
ters, radial distribution functions, density distributions, etc.
Numerous MD simulations have been performed concern-
ing molecular transport in membranes (15–23) including
relatively large molecules such as drugs (24–30). Addition-
ally, the dependence of DPPC flip-flop rate on cholesterol
concentration has been investigated (31). In this study, we
will use MD to predict translocation energy barriers and
gain insight into the interaction between DOX, water, and
a model membrane.METHODS
Molecular dynamics details
We used MD to study the interaction between DOX and a DPPC/Chol
membrane. Lennard-Jones forces were calculated with a cutoff of
1.6 nm. Electrostatic forces were found using the particle mesh Ewald
summation (32) with a real-space cutoff of 1 nm. We used GROMACS
4.0.5 (33) as the computational tool to perform MD. The GROMOS-based
force field of choice is referred to as 43A1-S3 (34). Force field parameters
(partial charges, bonding and nonbonding information) and structures for
Chol and DPPC have previously been optimized for this force field by
Chiu et al. (34). The structure of doxorubicin was taken from DrugBank
(35). To maintain consistency, bonding and nonbonding parameters for
all atoms on DOX were taken from the same force field as Chol and
DPPC. Partial charges on DOX were found using the Hartree-Fock method
and a 6-31G* basis set, solved with the program Gaussian (36) (see Table
S1, Fig. S1 in the Supporting Material for DOX partial charge specifica-
tions). All moieties containing oxygen, nitrogen, or phosphorous are repre-sented in full atomistic detail. The 43A1-S3 force field applies the united
atom model to all CH2 and CH3 groups. Water is explicitly represented
by the simple point charge model (37).
All simulations were run in the isobaric-isothermal NPT ensemble, using
a Berendsen thermostat with a relaxation time of 4 ps, and an anisotropic
Berendsen barostat set to 1 atm and a relaxation time of 8 ps. The thermo-
stat couples the system to a heat bath of 323 K, well above the phase tran-
sition temperature of the model DPPC at all relevant cholesterol
concentrations. Anisotropic pressure coupling allows for membrane
contraction and expansion independently in all dimensions.
Three systems were created with nearly identical numbers of lipids to
measure the effect of DOX on the properties of compatible bilayers.
Each system contained 1 DOX and ~6500 waters. The pure DPPC system
contains 128 DPPC molecules, the second system contains 110 DPPCs
and 20 Chol molecules, and the third contains 94 DPPCs and 40 Chols.
These systems therefore have mole fractions of 0% Chol, 15.4% Chol,
and 29.9% Chol, which for convenience will be referred to as 0% Chol,
15% Chol, and 30% Chol, respectively. The size of the systems is ~6 
6  10 nm. Because of periodic boundary conditions, there are periodic
images of DOX separated from one another in the xy plane by 6 nm. The
long-range interaction cutoff of 1.6 nm ensures that DOX effectively will
not see its periodic images. It has been shown experimentally that for
DOX in particular, permeability is independent of drug concentration (38).
Initial configurations were created from a preconstructed bilayer
composed of DPPC and Chol (39). To insert the drug, we decreased the
density of the bilayer by manually stretching it in the xy plane. The drug
was subsequently placed inside the stretched bilayer, which was then
shrunk to its original dimensions. Incremental equilibration was performed
with the steepest descent method, ranging from 1000 to 10,000 steps, and
MD simulation ranging from 200 ps to 1 ns, which allowed for stability
during expansion and shrinkage. Because the drug was not pulled, this
procedure was repeated for each individual simulation. Data were collected
after a minimum of 20 ns of further MD equilibration. The starting orien-
tation for the drug was such that the anthracycline backbone was perpen-
dicular to the bilayer normal. DOX cannot sample all configurations on
the time scale of nanoseconds, thus an equilibrium state is not obvious,
and the system may settle into a local free energy minimum.Potential of mean force
Because DOX translocation is on the order of minutes (40), and MD simu-
lations generally run on the order of 10–100 ns, we must force translocation
in our simulations. We fixed the center of mass of DOX at 1 A˚ intervals
from the center of mass of the bilayer (z ¼ 0 nm) to the bulk water
(z ¼ – 3.7 nm), leading to 38 independently created simulations per Chol
concentration. Because this constraint is only on the center of mass of
the drug in the z direction, DOX can freely rotate and translate in the xy
plane. The constraint is imposed by a very stiff spring having a tolerance
of 2  106 nm, allowing a calculation of the force on the spring.
The PMF at each position z0 along the drug’s path is represented here as
DG(z0). Because the constraint between the drug and the membrane is only
in the z direction, we can write the PMF (41) as
DGðz0Þ ¼ DGðz0Þ 
Z z0
z0
hFðzÞi dz: (1)
The negative sign ensures that a positive, attractive force between DOX
and the bilayer results in a decrease in the PMF. The mean force is
denoted < F(z) >, and is calculated with the final 4 ns of constraint force
data (4 106 data points for a time step of 1 fs). A plot of the mean force of
0% Chol simulations can be found in Fig. S2. Errors on the mean force are
the standard deviation of the mean forces of four 1 ns blocks making up the
total 4 ns block (each corresponding to 106 data points). We chose the bulk
water as the arbitrary initial position z0, because it is independent of compo-
sition, allowing us to easily compare the free energy profiles of the threeBiophysical Journal 101(2) 378–385
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380 Yacoub et al.systems. We defined the dimensions of the system with z0 ¼ 0 in the center
of the bilayer, and z0 ¼ – 3.7 nm as the maximum distance from the bilayer,
in the bulk water. The PMF then simplifies to
DGðz0Þ ¼
Z z0
3:7 nm
hFðzÞi dz : (2)
The PMF for each position z0 is thus exactly the work necessary to bring
the drug from the bulk water to z0. In these calculations DOX is able to
freely tilt and reorient. Steric hindrance may, however, bias DOX orienta-
tion and affect the calculation of the potential of mean force, meaning
that this calculation is an approximate one and the error should be consid-
ered a lower bound. The error in PMF was found by propagating the
constraint force error in the direction of translocation by summation.FIGURE 2 Potential of mean force, DG, as a function of the distance
between the centers of mass of DOX and the bilayer (ZDOX–BIL), for 0%
(black line, bottom), 15% (blue line, middle), and 30% (red line, top)
Chol systems. From left to right, the drug begins in the bulk water, pene-
trates into the center of the bilayer, and exits into the water on the opposite
side. Calculations were performed on one side of the membrane, and
assumed to be identical on the opposite side. The error is a propagation
of mean force errors. Error bars omitted on the left side for clarity.Order parameters
To characterize order in the bilayer we use an average order parameter,
<SZ>, where
SZ ¼ 1
2

3 cos2qi  1

(3)
is the order parameter for carbon i. Here, qi is the angle between the vector
bisecting carbons (i – 1) and (i þ 1) and the (vertical) membrane normal,
hence the subscript Z. The average order parameter for the carbons of all
DPPC tails is given by
hSZi ¼ 1
2N
XN
i
1
n
Xn
j
ðSZÞi; j : (4)
Here, N is the total number of DPPC lipids, n is the number of carbons
per acyl chain, excluding the first and last, and (SZ)i, j is the order parameter
for carbon j in chain i. The factor of two is due to the two tails of DPPC.
Perfect vertical orientation of the representative vector results in SZ ¼ 1,
whereas perfect horizontal orientation results in SZ ¼ – 1/2, for a random
distribution of angles <SZ> ¼ 0.RESULTS
DOX translocation
The potential of mean force is calculated for three systems
composed of 0%, 15%, and 30% Chol, for which Chol has
been shown (in the absence of DOX) to affect membrane
structure and molecular interactions to significantly
different degrees (31,42,43). As mentioned above, we calcu-
late the PMF beginning with DOX in the bulk water and
ending with DOX in the center of the bilayer (the values
from the center of the bilayer to the opposing bulk water
are assumed to be identical). Fig. 2 displays the three
PMF curves. The general trends in the free energy land-
scapes are held in common between the three compositions.
The drug begins in the isotropic water, experiencing a mean
force (and PMF) of close to zero (Figs. 2 and S2). As DOX
contacts the interface, the PMF characteristically decreases,
indicating overall attraction between DOX and the bilayer.
This decrease in free energy is attributed to the transfer of
the hydrophobic drug from water to an increasingly hydro-
phobic environment, as well as the electrostatic attraction
of DOX polar groups to charged DPPC headgroups. TheseBiophysical Journal 101(2) 378–385attractions pull the drug into the position of the PMF
minimum, at which point the mean force goes to zero.
From here, movement of DOX in either direction requires
energy to overcome the attraction of DOX to DPPC head-
groups. Moreover, further penetration into the membrane
requires an increase in free energy due to the steric
hindrance from DPPC acyl tails and cholesterol. Movement
of DOX back toward the bulk water is resisted due to hydro-
phobic/hydrophilic repulsion. Therefore, the PMFminimum
indicates relative equilibrium for DOX along the con-
strained coordinate, where the instantaneous forces in both
directions are, on average, equal. This position can be visu-
alized with Fig. 3, A–C. Here, we see snapshots of DOX at
the point of minimal free energy, which from Fig. 2 are ~19,
25, and 26 A˚ from the bilayer center for 0%, 15%, and 30%
Chol, respectively. Fig. 3 A shows that DOX prefers to parti-
tion mainly into the headgroups in a pure DPPC bilayer,
whereas in Fig. 3, B and C we see DOX partition on the
hydrophilic side of the interface. Fig. 3, D–F show DOX
in the center of the bilayer, a region of high free energy.
Note the ability of DOX to rotate around its center of mass.
To quantify the translocation process, we define the free
energy barrier, or activation energy, as the difference in
the PMF from the minimum to the highest maximum. We
find free energy barriers of 23.1 5 3.1 kBT, 36.8 5
5.1 kBT, and 54.5 5 4.7 kBT for the 0%, 15%, and 30%
Chol compositions, respectively. Based on Chol content,
Table 1 compares our results with related experimental
measurements. In terms of the dependence of energy barrier
on cholesterol, our results are in qualitative agreement with
experimental studies (40,44), as well as simulations of
DPPC flip-flop (31). The systems in this study and those
used by Regev et al. and Fre´zard et al. both involve phospho-
lipid membranes and are in the liquid (liquid disordered)
phase. We extracted the free energy barrier from the work
FIGURE 3 Snapshots (A–C) show 0%, 15%, and 30% Chol systems with
ZDOX–BIL ¼ 1.9, 2.5, and 2.6 nm, respectively, corresponding to the
most likely position of DOX based on the free energy minima in Fig. 2,
and (D–F) show the corresponding systems with the drug in the center.
Representations include water (blue), DPPC nitrogen (purple), DPPC phos-
phorous (green), and Chol oxygen (red). DOX is shown in a van der Waals
representation, with oxygen (red), hydrogen (white), nitrogen (blue), and
carbon (teal). Note the various degrees of water penetration, and the hori-
zontal Chol molecule bound to the drug in snapshot (E). DOX may act as
a facilitator of cholesterol flip-flop.
Cholesterol Role in Drug Translocation 381of Regev et al. using the Arrhenius equation on their Arrhe-
nius plot. The barrier found by Regev et al. is within our
error margins in the case of 0% Chol, providing a very reas-
suring result. Additionally, the free energy barrier of 37.2
kBT for a 20% Chol composition found by Fre´zard et al. is
close to our 15% Chol measurement (44) (Table 1). Our
results show self-consistency in the qualitative trend of these
free energy barriers with Chol, and remarkable quantitative
agreement with experimental results from similar systems.
Constraint-biased MD has shown here its utility as a tool for
measuring free energy barriers of molecular translocation.Membrane structure
The changes in structure induced by the presence of DOX
were analyzed by the systems both visually and by quanti-TABLE 1 Free energy barriers from MD simulations and
experiments
Source
Composition
(mol/mol) Chol content Activation energy
Regev et al. (40) 1:0 HSPC/Chol 0% Chol 20 kBT
Present work 1:0 DPPC/Chol 0% Chol 23.1 5 3.1 kBT
Present work 11:2 DPPC/Chol 15.4% Chol 36.85 5.1 kBT
Fre´zard et al. (44) 75:5:20 egg
PC/PA/Chol
20% Chol 37.2 kBT
Present work 9.4:4 DPPC/Chol 29.9% Chol 54.55 4.7 kBTfying a variety of properties. As seen in Fig. 3, D–F, DOX
has the ability to dramatically distort the membrane inter-
face. Consistent with previous observations of molecules
embedded in bilayers, we see DOX attracting headgroups
and allowing water penetration to varying degrees (22,31).
Additionally, the drug appears to pull cholesterol into the
center of the bilayer, perhaps facilitating cholesterol flip-
flop (see Fig. 3 E). Despite its relatively large hydrophobic
anthracycline backbone, DOX interacts electrostatically
with water and DPPC headgroups, through its hydroxyl,
ketone, and other polar sites (see Fig. 1). In Fig. 4 A, we
see DOX in the hydrophobic core of the bilayer. This simu-
lation contains 30% Chol, with DOX 1 A˚ from the center. In
addition to electrostatics, this distortion is due in large part
to the size of DOX, as it is large enough to interact with both
leaflets, yet too small to span the bilayer, creating a sort of
hydrophobic mismatch. Because of the symmetry of this
distortion, the net force on DOX is low and contributes to
the plateau in the 30% Chol curve in Fig. 2. Fig. 4 B shows
the same snapshot as Fig. 4 A, with everything but DOX and
water removed. By watching the trajectory of this simula-
tion, we see water molecules bind to DOX for periods of
time estimated on the order ~1 ps. These waters moveFIGURE 4 Snapshot of DOX in 30% Chol, with ZDOX–BIL ¼ 0.1 nm.
(A) DOX causes membrane curvature on both sides of the membrane by
attracting DPPC headgroups from both leaflets. (B) Shows (A) with every-
thing removed except the drug and water, showing water translocation.
Snapshots are rendered as in Fig. 3, with DOX reduced in thickness to
show its structure and interaction with water.
Biophysical Journal 101(2) 378–385
382 Yacoub et al.from one polar site on DOX to the next, and exit the bilayer
into the bulk water in either direction. This observation
illustrates the ability of DOX to induce water pores or
fingers and facilitate water translocation.
We analyzed this phenomenon graphically with a compar-
ison of species density distributions between the system
shown in Fig. 4 A and that of the same bilayer without
DOX present. Fig. 5 B shows the density profile for the
30% Chol system without DOX, showing a clear region of
bilayer interior free of headgroups and water. With DOX
in the center of the bilayer, Fig. 5 A shows a finite density
of water throughout the bilayer, and headgroups venturing
closer to the bilayer center. The asymmetric water density
profile is due to the asymmetric shape and irregular dis-
tribution of polar sites of DOX. There is also a general
broadening of density distributions for the representative
headgroup atoms of DPPC and Chol in the presence of
DOX (Fig. 5 A).
To understand the influence of DOX on membrane struc-
ture, we analyzed local and global changes in the average
DPPC acyl chain order parameter, <SZ>. Fig. 6 A shows
this parameter for local (within a 1.75 nm shell around
DOX center of mass) and global (beyond the shell) regions,
split into the leaflet containing DOX and the opposing
leaflet, for 0% Chol. The order of the system decreases
very slightly beyond the local shell, and very significantly
within the shell as DOX penetrates to the bilayer center.
Additionally, based on the similarity of the linear regres-
sions, both local and global orders are strongly coupled
between the leaflets. The local order is higher than the
global order for DOX positioned in the outer region of the
hydrophobic-hydrophilic interface. Though the extent of
local versus global order in Fig. 6 depends slightly on the
definition of the local shell, the observations above hold
for shell defined up to at least 3 nm (data not shown), and
the results are qualitatively identical for the 15% and 30%
Chol systems (shown in Fig. S3).
As the drug enters further toward the center, it slightly
expands the bilayer. Fig. 7 shows the area per lipid of-3 -2 -1 0 1 2 3
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FIGURE 5 Number density profiles in 30% Chol bilayers with DOX (A),
see Fig. 4, and without DOX (B). Colors correspond to Figs. 3 and 4. Repre-
sentations include water (blue), DPPC nitrogen (purple), DPPC phospho-
rous (green), Chol oxygen (red), and DOX (black). Note the penetration
of water and a general broadening of the head-group atom densities in
the presence of DOX.
Biophysical Journal 101(2) 378–385each system as a function of drug depth, with the area being
that of the xy plane. The area per lipid of the systems
without DOX are shown as dashed lines, with values of
63.9, 53.9, and 46.2 A˚2/lipid for the 0%, 15%, and 30%
Chol systems, respectively. These values agree with findings
of other studies (43), as do deuterium order parameters for
the drug-free systems (Fig. S4) (13,42). We see DOX cause
changes in the area per lipid on the order of 10% in our
6  6 nm systems.DISCUSSION
An interesting implication of Fig. 2 is that the limiting phys-
ical barrier of DOX translocation changes with bilayer
composition. Experimentally it has been assumed that the
rate determining step in translocation is flip-flop from one
leaflet to the other (38,40). In other words, this leaflet-leaflet
barrier (over the center of the bilayer), has been assumed to be
much greater than the leaflet-bulk barrier (release of DOX
into the water). Fig. 2 shows that for both 15% and 30%
Chol, this is what we predict, as the highest PMF maximum
is at the center of the bilayer. In the absence of cholesterol, the
highest maximum in the PMF is in the bulkwater. Flip-flop is
therefore not the rate determining step in our pure DPPC/
DOX system, meaning DOX moves from one leaflet to the
other frequently compared to its release from the interface.
A rough estimate of the ratio of rate constants of DOX flip-
flop, kflip–flop, to DOX release into the bulk water, krelease,
can be obtained from the difference in free energy barrier
between the two processes. Namely, it is given by
kflipflop
krelease
¼ expDGflipflop  DGreleasekBT: (5)
On the basis of the results presented in Fig. 2, DOX flip-
flops on the order of 103 times per release in the absence of
Chol. Because Chol alters the physical barrier, DOX flip-
flops only once every 109 times it is released to the water
in the case of 15%, and once every 1016 times for 30% Chol.
A key aspect of the change in maximal free energy barrier
is the effect of membrane structure on the most probable
position of DOX. Fig. 3 A shows that, in the absence of
cholesterol, DOX prefers to partition within the headgroups
of DPPC. Fig. 7 shows, as is well known, that the area per
lipid depends heavily on Chol concentration. As the area
per lipid decreases with added Chol, an increasingly dense
bilayer prevents DOX from positioning itself on the inside
of the interface (Fig. 3, B and C). This effectively reduces
the depth at which the net force between DOX and the
bilayer is attractive, thus raising the PMF minimum and
decreasing the leaflet-bulk free energy barrier from 0% to
15% Chol and from 15% to 30% Chol (Fig. 2). Likewise,
as the area per lipid decreases, the membrane resists entry
of DOX into the membrane interior. The steep slope in the
30% Chol PMF curve, rising from the PMF minimum to
the bilayer center, corresponds to a highly negative,
FIGURE 6 (A) Average DPPC order parameters,
<SZ>, as a function of DOX-bilayer distance,
ZDOX–BIL. To elucidate structural effects of DOX,
the bilayer is split into four regions, as denoted in
the legend of (A) and the corresponding colored
regions of snapshot (B). Open data points account
for DPPC with phosphorous within a 1.75 nm shell
of the drug in the xy plane, while solid points are for
chains beyond the shell. The simulation shown in
(B) thus contributes the four data points at
ZDOX–BIL ¼ 0.9 nm in (A). Lines are regressions
as a guide for the eye.Note strong coupling between
leaflets, even with DOX far from the center.
Cholesterol Role in Drug Translocation 383repulsive force, between the bilayer and DOX. This repul-
sion increases the leaflet-leaflet free energy barrier with in-
creasing Chol. By condensing the bilayer, cholesterol thus
has the ability to induce a transition in the dominant phys-
ical barrier, as it causes both a decrease in the leaflet-bulk
barrier and an increase in the leaflet-leaflet barrier. We
postulate that transitions of this nature will predict the
Chol concentration at which abrupt changes in membrane
properties are observed. As an example, Rebolj et al. have
seen ostreolysin membrane activity jump dramatically at
30% Chol, associated with the creation of a liquid-ordered
domain (45).
We observe in our simulations, i.e., Fig. 4, the specific
effects of the shape, size, and chemical structure of doxoru-
bicin on membrane structure. Fig. 7 shows that, with respect
to the area per lipid without DOX, the drug generally
induces a decrease in the total area per lipid on the hydro-
philic side of the interface. This observation is accompanied
by an increase in local DPPC order (Fig. 6). We explain this
finding with Fig. 3, B and C, which show DOX horizontal,
above DPPC headgroups. The electrostatic attraction of
DOX polar groups to the zwitterionic DPPC headgroups
encourages the lipids to aggregate closer than they other-
wise would, decreasing the area per lipid and compacting-4 -3 -2 -1 0
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FIGURE 7 Area per lipid as a function of the distance between the center
of mass of DOX from the center of the bilayer, ZDOX–BIL. Dashed lines
correspond to the area per lipid calculated in DOX-free systems.DPPC tails. Fig. 6 shows that even with DOX over 2 nm
from the opposing leaflet, DPPC order is virtually paralleled
between leaflets, indicating a very strong, short-range inter-
leaflet coupling in lipid order.
It is worth noting the implications of these results on the
question of whether DOX is charged during translocation.
Several simulation studies have discussed the effect of
charge on molecular translocation (25,28,30). Charge has
a dramatic effect on the potential free energy barrier in all
of these studies, making the question pressing. In general,
charging a molecule will change the barrier from leaflet-
leaflet to leaflet-bulk or vice versa. Our calculations of the
free energy barriers found for the neutral doxorubicin
molecule agree well with values found experimentally
(40,44). Thus, DOX is most likely neutral as it travels
through the membrane, otherwise our results would likely
be in dramatic disagreement.CONCLUSIONS
We have analyzed the potential of mean force characterizing
the translocation of doxorubicin across a DPPC/Chol
membrane. Free energy barriers of 23.1 5 3.1 kBT,
36.8 5 5.1 kBT, and 54.5 5 4.7 kBT have been found for
0%, 15%, and 30% Chol, respectively. However, the effect
of cholesterol on DOX translocation is not only quantitative.
Beneath these values lies a qualitative transition in the
mechanism of translocation. In the cases of 15% to 30%
Chol, the maximum in the free energy is in the center of
the bilayer, in agreement with the belief in flip-flop-limited
translocation. However, in the case of 0% Chol, the free
energy maximum is in the bulk water, and the limiting
step in translocation is then the release of DOX into the
bulk water. Thus, not only does DOX prefer to be inside
the bilayer without cholesterol present, it actually flip-flops
very rapidly (103 times faster) compared to its release from
the bilayer.
Doxorubicin is a relatively large, complex drugwithmany-
polar sites, for whichmolecular volume is indeed not the only
factor in translocation and membrane deformation. This is
shown most dramatically in Fig. 4, where the attraction ofBiophysical Journal 101(2) 378–385
384 Yacoub et al.DOX active sites to DPPC deforms the bilayer and allows
water penetration. Based on Fig. 6 we estimate the propaga-
tionofDPPCdisorder to dissipate 2–4nm from thedrug.Con-
strained MD provides a thought-provoking and applicable
tool in the study of molecular transport across model
membranes. It will be interesting to investigate the interac-
tions between various drugs and lipid compositions. By
measuring the most optimal drug depth, we can determine
the dominant physical barrier, characterize drug hydropho-
bicity, and ultimately gain insight into the nature of drug-
bilayer interaction. Both theoretical and experimental
methods will be required to comprehensively understand
drug-bilayer interactions in liposomal drug carriers. This
study represents one step in the effort to predict drug-release
profiles and optimize the composition and design of lipo-
somal drug carriers. Small changes in liposome composition
may provide more accurate release profiles for specific drugs.SUPPORTING MATERIAL
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